medRxiv
October 19, 2026
Joel Gelernter, Jack Hirsch, Cassie M. Overstreet et al.
preprint
Frequent nightmares affect roughly 2-6% of the population and may reflect underlying psychopathology, such as post-traumatic stress disorder (PTSD), or, when recurrent and distressing, be diagnosed as nightmare disorder (ND). The genetic basis of nightmares remains poorly understood. We performed a genome-wide association study (GWAS) meta-analysis of nightmare frequency (NF) across 207,243...
The International Journal of Neuropsychopharmacology
September 9, 2026
Marta Di Forti, Isabelle Austin-Zimmerman, Edoardo Spinazzola et al.
Abstract Background Epidemiological data have consistently shown an association between heavy cannabis use and increased risk of psychotic disorders. Nevertheless, not all cannabis users develop the illness. Evidence from other substance of abuse such as Alcohol suggest how genetic differences in enzymes involved in its metabolism influence individual response to the drug. No studies to data...
International Journal of Molecular Sciences
May 15, 2022
Uri Bright, Irit Akirav
42 citations
Depression is characterized by continuous low mood and loss of interest or pleasure in enjoyable activities. First-line medications for mood disorders mostly target the monoaminergic system; however, many patients do not find relief with these medications, and those who do suffer from negative side effects and a discouragingly low rate of remission. Studies suggest that the endocannabinoid...
Uri Bright, Suhas Ganesh, Daniel F. Levey et al.
Abstract Background Cannabis is one of the most widely used psychoactive substances worldwide. Δ 9 -tetrahydrocannabinol (Δ 9 -THC) is the main contributor to cannabis-induced effects such as euphoria, anxiety, and psychotomimetic effects, and is metabolized by several hepatic enzymes, including CYP3A4. There are interindividual differences in how cannabis affects users, which have substantial...